Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Day One Biopharmaceuticals
Acquired Company
Mersana Therapeutics
BrisbaneCambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Day One Biopharmaceuticals has announced their acquisition of Mersana Therapeutics for approximately $130 million. Mersana shareholders will receive an upfront cash payment combined with milestone-based contingent value rights. This acquisition reflects Day One's strategy to diversify its pipeline and enhance its oncology offerings.
Fundz sees it the moment Day One Biopharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Mersana Therapeutics?
Mersana Therapeutics was acquired by Day One Biopharmaceuticals, based in Brisbane. The deal was reported on November 30, 2025. Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. Day One Biopharmaceuticals is privately held and operates in Biotechnology.
When did Day One Biopharmaceuticals acquire Mersana Therapeutics?
Day One Biopharmaceuticals's acquisition of Mersana Therapeutics was reported on November 30, 2025. Day One Biopharmaceuticals has announced their acquisition of Mersana Therapeutics for approximately $130 million. Mersana shareholders will receive an upfront cash payment combined with milestone-based contingent value rights. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mersana Therapeutics do?
Mersana Therapeutics, Inc. is a biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Their innovative ADC platform enables the design of more effective cancer therapies. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.